PanGenomic Health, Inc. Class A (TSE:NARA)
:NARA
Want to see TSE:NARA full AI Analyst Report?
Top Page
PanGenomic Health, Inc. Class A
(NARA)
Select Model
Select Model
Rating:45Neutral
Price Target:
C$0.38
▼(-25.49% Downside)
Action:Reiterated
Date:05/06/26
The score is primarily constrained by weak financial performance—minimal revenue, persistent losses, ongoing cash burn, and negative equity that elevates financing risk. Technical indicators are mixed with some near-term stabilization signals but a clear longer-term downtrend. Valuation is also limited by negative earnings and no provided dividend yield.
Positive Factors
Industry positioning
Operating in healthcare information services aligns the business with durable secular demand for digital health data, analytics, and software. That structural market growth supports long-term commercial opportunity if the company can productize offerings and capture recurring revenue streams.
Negative Factors
No revenue
The company reports essentially no revenue for multiple years, leaving its core business model unproven. Without recurring sales, the firm cannot self-fund growth or demonstrate product-market fit, making long-term viability dependent on external capital and execution risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Industry positioning
Operating in healthcare information services aligns the business with durable secular demand for digital health data, analytics, and software. That structural market growth supports long-term commercial opportunity if the company can productize offerings and capture recurring revenue streams.
Read all positive factors
PanGenomic Health, Inc. Class A (NARA) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$5.48M
Dividend YieldN/A
Average Volume (3M)110.39K
Price to Earnings (P/E)―
Beta (1Y)0.74
Revenue GrowthN/A
EPS Growth85.58%
CountryCA
Employees5
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-0.23
Shares Outstanding14,046,870
10 Day Avg. Volume77,322
30 Day Avg. Volume110,395
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)-3.87
Price to Sales (P/S)0.00
P/FCF Ratio-4.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PanGenomic Health, Inc. Class A Business Overview & Revenue Model
Company Description
Pangenomic Health Inc., a precision health company, develops a self-care digital platform to deliver personalized and evidence-based information about natural treatments to support mental health. It develops the Nara App, a mobile app that provide...
PanGenomic Health, Inc. Class A Financial Statement Overview
Summary
Income Statement
6
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
12
Very Negative
| Breakdown | Dec 2025 | Jun 2025 | Jun 2024 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -628.00 | ― | -681.43K | -11.11K | -2.13K |
| EBITDA | -3.42M | ― | -2.71M | -3.57M | -847.50K |
| Net Income | -3.43M | -3.80K | -2.97M | -20.35M | -2.65M |
Balance Sheet | |||||
| Total Assets | 160.91K | 39.16K | 71.48K | 504.14K | 2.58M |
| Cash, Cash Equivalents and Short-Term Investments | 38.77K | 1.31K | 12.56K | 88.53K | 1.35M |
| Total Debt | 212.87K | 0.00 | 964.75K | 101.77K | 0.00 |
| Total Liabilities | 2.35M | 2.44M | 2.22M | 719.25K | 334.45K |
| Stockholders Equity | -2.19M | -2.41M | -2.14M | -215.11K | 2.24M |
Cash Flow | |||||
| Free Cash Flow | -1.88M | -58.25K | -1.57M | -2.79M | -1.07M |
| Operating Cash Flow | -1.88M | -58.25K | -1.57M | -2.78M | -1.06M |
| Investing Cash Flow | 0.00 | 0.00 | -3.14K | -52.13K | -604.91K |
| Financing Cash Flow | 1.92M | 47.00K | 1.50M | 1.57M | 2.97M |
PanGenomic Health, Inc. Class A Technical Analysis
Negative
0.51
Price Trends
0.43
Negative
0.47
Negative
1.01
Negative
Market Momentum
>-0.01
Positive
43.09
Neutral
13.13
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:NARA, the sentiment is Negative. The current price of 0.51 is above the 20-day moving average (MA) of 0.46, above the 50-day MA of 0.43, and below the 200-day MA of 1.01, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 43.09 is Neutral, neither overbought nor oversold. The STOCH value of 13.13 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:NARA.
PanGenomic Health, Inc. Class A Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | C$48.43M | -2.31 | -207.53% | ― | 15725.47% | -26.12% | |
45 Neutral | C$5.48M | -2.47 | ― | ― | ― | 85.58% | |
45 Neutral | C$24.08M | -9.48 | 3086.87% | ― | -46.50% | 1.32% | |
45 Neutral | C$2.89M | -4.56 | -34.06% | ― | -100.00% | 34.51% | |
42 Neutral | C$8.64M | -5.12 | 6239.15% | ― | ― | 68.00% | |
| ― | C$7.43M | -21.40 | 527.45% | ― | ― | -61.90% |
* Healthcare Sector Average
TSE:NARA
PanGenomic Health, Inc. Class A
0.39
0.21
116.67%
TSE:ADK
Diagnos
0.19
-0.05
-20.83%
TSE:NDAT
nDatalyze Corp
0.07
0.05
250.00%
TSE:AIDR
Rocket Doctor AI
0.59
0.18
43.90%
TSE:UDOC
UniDoc Health Corp
0.12
-0.18
-61.02%
TSE:DMED
DiagnaMed Holdings Corp.
0.06
0.03
100.00%
PanGenomic Health, Inc. Class A Corporate Events
Business Operations and StrategyM&A TransactionsPrivate Placements and Financing
PanGenomic Health Moves to Acquire Ayla BioScience in All-Share Deal
Positive
Apr 14, 2026
PanGenomic Health Inc. has signed a non-binding Letter of Intent to acquire all outstanding shares of Ayla BioScience Inc., a U.S.-headquartered, vertically integrated biomanufacturing company with operations in Colombia that develops advanced fun...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.